Lotus Pharmaceutical Co., Ltd. (TPE:1795)
186.50
+2.50 (1.36%)
Aug 19, 2026, 1:30 PM CST
Lotus Pharmaceutical Revenue
Lotus Pharmaceutical had revenue of 8.81B TWD in the quarter ending June 30, 2026, with 85.56% growth. This brings the company's revenue in the last twelve months to 28.49B, up 48.98% year-over-year. In the year 2025, Lotus Pharmaceutical had annual revenue of 20.51B with 10.36% growth.
Revenue (ttm)
28.49B
Revenue Growth
+48.98%
P/S Ratio
1.74
Revenue / Employee
25.92M
Employees
1,099
Market Cap
49.65B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.51B | 1.93B | 10.36% |
| Dec 31, 2024 | 18.58B | 1.63B | 9.59% |
| Dec 31, 2023 | 16.96B | 2.33B | 15.89% |
| Dec 31, 2022 | 14.63B | 1.98B | 15.68% |
| Dec 31, 2021 | 12.65B | 1.92B | 17.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals | 19.56B |
| Grape King Bio | 10.28B |
| YungShin Global Holding | 7.84B |
| Standard Chemical & Pharmaceutical | 7.08B |
| TTY Biopharm Company | 6.65B |
| Synmosa Biopharma | 6.37B |
| ScinoPharm Taiwan | 3.07B |
| Center Laboratories | 1.66B |